The Technical Analyst
Alimera Sciences Inc [ALIM]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Alimera Sciences Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
5.99% $3.54
America/New_York / 22 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 185.33 mill |
| EPS: | -0.840 |
| P/E: | -4.21 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 52.35 mill |
| Avg Daily Volume: | 0.0736 mill |
| RATING 2024-04-22 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.21 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.09x |
| Company: PE -4.21 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 3.30 - 3.78 ( +/- 6.78%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-26 | Ashman Philip | Sell | 12 103 | Common Stock |
| 2024-03-11 | Werner Jason M. | Buy | 1 800 | Restricted Stock Units |
| 2024-03-11 | Wood Todd Michael | Buy | 125 000 | Performance-Based Restricted Stock Units |
| 2024-03-11 | Wood Todd Michael | Buy | 125 000 | Restricted Stock Units |
| 2024-03-11 | Eiswirth Richard S Jr | Buy | 14 700 | Restricted Stock Units |
| INSIDER POWER |
|---|
| 27.00 |
| Last 77 transactions |
| Buy: 33 555 909 | Sell: 20 075 544 |
Forecast:
16:00 - $3.58
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $3.58
Forecast 2: 16:00 - $3.58
Forecast 3: 16:00 - $3.58
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.54 (5.99% ) |
| Volume | 0.0260 mill |
| Avg. Vol. | 0.0736 mill |
| % of Avg. Vol | 35.26 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ALIM
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ALIM
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Latest Press Releases
2024-03-19 08:00:00 - Press Release
Alimera Announces First Patient Randomized In Radiation Retinopathy Trial Being Conducted By The Drcr Retina Network
Protocol al is studying iluvien or faricimab (6.0 mg) injections versus observation for the prevention of visual acuity loss due to radiation retinopathy protocol al is studying iluvien or faricimab (6.0 mg) injections versus observation for the prevention of visual acuity loss due to radiation retinopathy
2024-03-07 07:30:00 - Press Release
Alimera Sciences Reports Fourth Quarter And Full Year 2023 Results
Q4 net revenues up 88% to $26.3 million vs. q4 2022 2023 net revenues up 49% to $80.8 million vs. 2022 increases 2024 revenue guidance
2024-02-08 08:00:00 - Press Release
The Uk National Institute For Health And Care Excellence (nice) Issues Final Draft Guidance To Provide Patients With A Natural Lens (phakic Eye) Being Treated For Chronic Diabetic Macular Edema Access To Iluvien®
Nice final draft guidance recommends providing national health system (nhs) patients with a phakic lens access to the only sustained-release treatment lasting up to 36 months for chronic diabetic macular edema (dme) nice final draft guidance recommends providing national health system (nhs) patients with a phakic lens access to the only sustained-release treatment lasting up to 36 months for chronic diabetic macular edema (dme)
2024-01-02 08:00:00 - Press Release
Alimera Sciences Names Elliot Maltz As Chief Financial Officer And Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atlanta, jan. 02, 2024 (globe newswire) -- alimera sciences, inc. (nasdaq: alim) (“alimera” or the “company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced that elliot maltz, c.p.a., has been named chief financial officer effective immediately.
2023-12-12 07:30:00 - Press Release
Alimera Sciences Appoints Todd Wood As President Of U.s. Operations And Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atlanta, dec. 12, 2023 (globe newswire) -- alimera sciences, inc. (nasdaq: alim) (“alimera” or the “company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced the appointment of todd wood as president u.s. effective immediately.
Latest News
2024-03-13 09:01:12 - Zacks Investment Research
New Strong Sell Stocks for March 13th
ASLE, ALIM and CADE have been added to the Zacks Rank #5 (Strong Sell) List on March 13, 2024.
2024-03-07 10:01:28 - Zacks Investment Research
Alimera Sciences (ALIM) Reports Q4 Loss, Tops Revenue Estimates
Alimera Sciences (ALIM) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.54 per share a year ago.
2023-08-10 10:00:16 - Zacks Investment Research
Alimera Sciences (ALIM) Reports Q2 Loss, Lags Revenue Estimates
Alimera Sciences (ALIM) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.45 per share a year ago.
2023-08-02 11:43:00 - GlobeNewsWire
Alimera Sciences to Report Second Quarter 2023 Financial Results on August 10, 2023, and Provide Corporate Update
ATLANTA, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report second quarter financial results on August 10, 2023, prior to the market open. Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments.
2023-06-08 09:52:16 - Zacks Investment Research
Alimera Sciences (ALIM) Is Attractively Priced Despite Fast-paced Momentum
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Alimera Sciences (ALIM) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
2023-06-01 10:49:28 - Zacks Investment Research
Are Medical Stocks Lagging Alimera Sciences (ALIM) This Year?
Here is how Alimera Sciences (ALIM) and Haemonetics (HAE) have performed compared to their sector so far this year.
2023-05-25 11:17:03 - Zacks Investment Research
Alimera (ALIM) Completes Enrollment in Eye Disease Study
Alimera (ALIM) announces completion of patient enrollment in its NEW DAY study to evaluate Iluvien 0.19 mg as a baseline therapy in diabetic macular edema. The stock surges 8% on Wednesday.
2023-05-23 09:53:14 - Zacks Investment Research
Alimera Sciences (ALIM) Shows Fast-paced Momentum But Is Still a Bargain Stock
Alimera Sciences (ALIM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
2023-05-19 13:46:54 - Zacks Investment Research
Alimera (ALIM) Up on Deal With Eyepoint for U.S. Rights to Yutiq
Alimera Sciences ALIM announced acquiring additional U.S. commercialization rights for 0.18 mg dose strength of Yutiq from EyePoint Pharmaceuticals, Inc. Yutiq is indicated to treat chronic non-infectious uveitis affecting the posterior segment of the eye.
2023-05-19 06:00:00 - PennyStocks
How to Develop a Penny Stocks Trading Mentality
Can these tips help you become a better penny stocks trader? The post How to Develop a Penny Stocks Trading Mentality appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.